Key Takeaways
- Strong quarter driven by order book execution: Revenue growth reflects ramp-up of commercial molecules, improved capacity utilization, and conversion of the order book, with LOIs and contracts contributing over INR 250 crores in 9MFY26.
- Agro demand shows clear recovery: Channel inventory levels are improving and global demand is normalizing, driving a healthy revival in customer offtake.
- Jayhawk acquisition adds US manufacturing: The deal provides an onshore US asset, access to new end markets, and is expected to be EPS accretive from day one, with closing imminent.
- Pharma and Polymer pipelines are deep: Over 65 molecules are in R&D and pilot stages across Pharma and Performance Materials, supporting future growth visibility.
- What to watch next quarter: The Jayhawk integration and its consolidated financial contribution, the pace of working capital improvement toward the sub-200 day target, and whether Agro recovery momentum sustains.
Jayhawk Acquisition: Strategic Rationale & Impact
- Onshore US manufacturing: The acquisition of Jayhawk Fine Chemicals provides a critical manufacturing asset base in the US, enabling a strong local supply chain proposition for American customers.
- End market diversification: The deal enhances access to semiconductors, automotive, EV, Pharma, aviation, and electronics end markets, broadening the company's sectoral reach.
- Financial profile: The transaction is expected to be EPS accretive from day one, with no contribution yet reflected in Q3 or 9MFY26 results. Consolidation will begin after closing, expected in the coming weeks.
- Integration focus: Smooth integration of Jayhawk is a stated near-term priority, alongside deepening relationships with global innovators.
Vishal Thakkar: "One, we get a critical manufacturing asset base in US, which is a very important asset that would be there, especially when we are looking at attracting clients in the US market. As we are able to offer a very strong local supply chain for them."
Demand Environment & Vertical Performance
- Agro recovery underway: The Agro vertical showed a clear recovery, supported by improving channel inventory levels and a gradual normalization of global demand, reflected in healthier customer offtake.
- Pharma as a growth driver: The Pharma segment continues to perform strongly, with a focus on import substitution of key starting materials and intermediates for high-growth, high-value end products.
- Performance Materials momentum: The portfolio, including defense and electronic materials, delivered strong growth during the quarter.
- Japan geography traction: Growth was supported by increasing engagement with new customer additions and the expansion of new molecules within existing customer relationships.
Pipeline & R&D Engine
- Pharma pipeline depth: More than 30 molecules are currently in R&D and pilot stages within the Pharma segment alone, indicating a robust future revenue stream.
- Polymer and Electronic Materials pipeline: Over 35 molecules are under development and in pilot stages, reinforcing the growth outlook for the Performance Materials vertical.
- Combined innovation funnel: The aggregate pipeline across Pharma and Polymers stands at 65+ molecules, providing strong visibility into future commercialization opportunities.
Competitive Position & Customer Relationships
- Preferred partner status: The company attributes its strong customer relationships to three factors: technical capabilities across multiple chemistries, supply chain access, and a multi-year track record of reliability with multinational customers.
- Order book conversion: The quarter's growth was materially driven by the ramp-up of execution against the existing order book, demonstrating the conversion of long-term contracts into revenue.
Vishal Thakkar: "So if you were to ask me, there are two or three broad ones. One, technical capabilities across multiple chemistries. Two, the access to supply chain. And three, an effort of over years together to work with a multinational company like that and references that we have created that as a very reliable, sustainable supply chain partner is what brings us to being a preferred partner with these customers."
Balance Sheet & Working Capital
- Working capital trajectory: Working capital intensity remained broadly in line with the previous quarter, with the downward trend in working capital days continuing.
- Near-term target: Management aims to reduce working capital days to a 220-200 day range in the near term.
- FY27 ambition: The objective for FY27 is to bring working capital below 200 days, targeting around 180 days or below.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Jayhawk transaction close | Complete formalities and close the acquisition | "Coming weeks" |
| Jayhawk financial consolidation | Add Jayhawk revenue and profit to consolidated numbers | Starting next quarter |
| Working capital improvement | Reduce to 220-200 days | Near term |
| Working capital improvement | Reduce to ~180 days or below | FY27 |
| Growth momentum | Sustain growth momentum into next fiscal year, supported by pipeline visibility and global footprint expansion | Next fiscal year |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹512 cr, up 31% YoY |
| EBITDA | ₹130 cr |
| EBITDA margin | 25% |
| PAT | ₹61 cr, up 12% YoY |
| 9MFY26 revenue | ₹1,730 cr, up 84% YoY |
| 9MFY26 EBITDA | ₹402 cr, up 53% YoY |
| 9MFY26 EBITDA margin | 23% |
| 9MFY26 PAT | ₹166 cr, up 71% YoY |
| Pharma segment revenue share | 19% of sales for 9MFY26 |
| Performance Material revenue share | 17% of revenue for 9MFY26 |
| Pharma segment growth | 85% YoY in 9MFY26 |
| Polymer and Performance Material segment growth | 245% YoY in 9MFY26 |
| Japan revenue contribution | ~17% of revenue in Q3 |
| Export revenue share | 58% of total revenue |
| LOI and contract revenue conversion | >₹250 cr in 9MFY26 |
| Working capital days | ~250 days consolidated; near-term target 220-200 days, FY27 target below 200, around 180 days or below |